Literature DB >> 24156960

Percutaneous coronary intervention versus medical therapy in stable coronary artery disease: the unresolved conundrum.

Stephen E Epstein1, Ron Waksman, Augusto D Pichard, Kenneth M Kent, Julio A Panza.   

Abstract

One of the major dilemmas facing physicians is what diagnostic and therapeutic approaches should be recommended to those stable coronary artery disease patients whose symptoms are adequately controlled on medical therapy. This study sought to assess the evidence-based data relating to whether: 1) all patients with significant coronary lesions (i.e., ischemia-producing) should undergo percutaneous coronary intervention (PCI); 2) the best therapeutic approach is optimal medical therapy; or 3) PCI should be performed, but only in certain subsets of patients. We reviewed all recent meta-analyses of prospective randomized trials that compared the outcomes of medical therapy and PCI in stable, symptomatically controlled, coronary artery disease patients. To provide greater insights to the clinician, we then analyzed, in depth, 3 comprehensive and widely quoted randomized trials. Review of recently published (2012) meta-analyses, and the detailed analyses of 3 widely quoted individual studies, indicate no difference exists between PCI and medical therapy in nonfatal MI or in all-cause or cardiovascular mortality. Thus, clinical equipoise exists: in other words, there is no evidence-based justification for adopting 1 therapeutic strategy over the other. Therefore, it is not inappropriate, until additional evidence emerges, for the responsible, experienced physician to weigh several sources of information in formulating a recommendation to the patient, even though definitive evidence-based data are not as yet available. Such sources may include assessment of the individual patient's clinical presentation, assessment of the severity of ischemia, and the patient's precise coronary anatomy. Critical for more-reliable decision making will be future development of accurate measures of the individual patient's risk of MI and/or death, whether by biomarker, imaging, or ischemia assessments.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CABG; CAD; FFR; MI; OMT; PCI; VH-IVUS; clinical equipoise; coronary artery bypass graft; coronary artery disease; dilemma; fractional flow reserve; myocardial infarction; optimal medical therapy; percutaneous coronary intervention; stable CAD; virtual histology intravascular ultrasound

Mesh:

Substances:

Year:  2013        PMID: 24156960     DOI: 10.1016/j.jcin.2013.07.003

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  4 in total

1.  Association of Medical Liability Reform With Clinician Approach to Coronary Artery Disease Management.

Authors:  Steven A Farmer; Ali Moghtaderi; Samantha Schilsky; David Magid; William Sage; Nori Allen; Frederick A Masoudi; Avi Dor; Bernard Black
Journal:  JAMA Cardiol       Date:  2018-07-01       Impact factor: 14.676

2.  In-hospital prognosis and long-term mortality of STEMI in a reperfusion network. "Head to head" analisys: invasive reperfusion vs optimal medical therapy.

Authors:  C García-García; N Ribas; L L Recasens; O Meroño; I Subirana; A Fernández; A Pérez; F Miranda; H Tizón-Marcos; J Martí-Almor; J Bruguera; R Elosua
Journal:  BMC Cardiovasc Disord       Date:  2017-05-26       Impact factor: 2.298

3.  Higher serum lectin-like oxidized low-density lipoprotein receptor-1 in patients with stable coronary artery disease is associated with major adverse cardiovascular events: A multicentre pilot study.

Authors:  Zi-Wen Zhao; Yi-Wei Xu; Shu-Mei Li; Jin-Jian Guo; Tao Yi; Liang-Long Chen
Journal:  Biochem Med (Zagreb)       Date:  2019-02-15       Impact factor: 2.313

4.  Variation in Management of Patients With Obstructive Coronary Artery Disease: Insights From the Veterans Affairs Clinical Assessment and Reporting Tool (VA CART) Program.

Authors:  Amneet Sandhu; Maggie A Stanislawski; Gary K Grunwald; Kathryn Guinn; Javier Valle; Daniel Matlock; P Michael Ho; Thomas M Maddox; Steven M Bradley
Journal:  J Am Heart Assoc       Date:  2017-09-12       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.